Results 171 to 180 of about 12,338 (219)

Functional high‐risk phenotype predicts poor survival in multiple myeloma independent of front‐line treatment: A secondary analysis of CIBMTR data

British Journal of Haematology, Volume 208, Issue 6, Page 2134-2142, June 2026.
Summary Functional high‐risk (FHR) multiple myeloma (FHRMM) is often defined as progression within 12–24 months of front‐line autologous hematopoietic stem cell transplantation (AHSCT). For patients with early progression after suboptimal front‐line therapies, it is challenging to assign the disease progression to a true FHR phenotype versus less ...
Utkarsh Goel, Catalin Dragomirescu, Saurabh Zanwar, Rafaella Cassano Cassano, Kara I. Cicero, Andrew J. Cowan, Rahul Banerjee, Faiz Anwer, Jack Khouri, Danai Dima   +9 more
wiley   +1 more source

Enhancing antitumour response to proteasome inhibitors with inhibitors of insulin‐degrading enzyme, a new molecular vulnerability in multiple myeloma

British Journal of Pharmacology, Volume 183, Issue 12, Page 3355-3376, June 2026.
Inhibitors of insulin‐degrading enzyme boost PI cytotoxicity through an increased sensitivity of proteasome to PI inhibitors, induction of ISR, DNA damage and Myc down‐regulation. They overcome PI resistance in vitro and induce tumour regression in vivo.
Laetitia Lesire, Rebecca Deprez‐Poulain, Damien Bosc, Florence Leroux, Valerie Landry, Sarah Ourabah, Morgane Tardy, Clara Maillard, Ronan Gealageas, Julie Dumont, Adrien Herledan, Sandrine Warenghem, Manon Cruette, Celine Lenglart, Alexandre Biela, Catherine Piveteau, Eva De Smedt, Catharina Muylaert, Wenguang Liang, Elvira Garcia De Paco, Elina Alaterre, Sara Ovejero, Nicolas Robert, Fabien Delahaye, Wei‐Jen Tang, Peter van Endert, Elke De Bruyne, Jérôme Moreaux, Benoit Deprez   +28 more
wiley   +1 more source

Targeting Ikaros and Aiolos: Next‐Generation Cereblon E3 Ligase Modulators in MM

European Journal of Haematology, Volume 116, Issue 6, Page 697-708, June 2026.
The graphical abstract illustrates the mechanism of action of cereblon E3 ligase modulators (CELMoDs) in multiple myeloma, highlighting cereblon‐mediated degradation of IKZF1 and IKZF3. Compared with classical immunomodulatory drugs (IMiDs), CELMoDs induce deeper IKZF1/3 depletion, leading to more pronounced suppression of the IRF4–MYC survival axis ...
Maria Eugenia Alvaro, Enrica Antonia Martino, Santino Caserta, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Plenary Abstracts Session & Oral Presentations

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Positioning of Melflufen in Heavily Pretreated RRMM Patients: Real‐World Evidence in a Rapidly Evolving Therapeutic Landscape

European Journal of Haematology, Volume 116, Issue 6, Page 928-936, June 2026.
ABSTRACT Modern therapies have clearly marked the history of multiple myeloma (MM), leading to undisputed advantages in terms of sustained responses and prolonged survival, while progressively improving patients' quality of life. Nonetheless, disease recurrence and resistance to available therapies underscore the importance of identifying additional ...
K. Mancuso, S. Masci, M. Talarico, A. Vitale, S. Barbato, V. Solli, M. Puppi, I. Rizzello, L. Pantani, P. Tacchetti, M. Iezza, R. Restuccia, I. Sacchetti, E. Manzato, S. Ghibellini, S. Armuzzi, B. Taurisano, M. Cavo, E. Zamagni   +18 more
wiley   +1 more source

Poster Sessions

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Detection of vascular amyloid deposits in a bone marrow aspirate

British Journal of Haematology, Volume 208, Issue 6, Page 1907-1908, June 2026.
Konstantinos Liapis, Georgios Kanellis, Georgios Vrachiolias, Evangelia Charitaki   +3 more
wiley   +1 more source

Clinicopathological and transcriptomic profiles of 101 patients with diffuse large B‐cell lymphoma/high‐grade B‐cell lymphoma with double‐hit MYC and BCL2 or BCL6 and triple hit

Histopathology, Volume 88, Issue 7, Page 1324-1347, June 2026.
Diffuse large B‐cell lymphoma/high‐grade B‐cell lymphoma (DLBCL/HGBCL) is a mature aggressive B‐cell lymphoma. This article performed a comprehensive clinicopathological and transcriptomic analyses of this lymphoma category. Aims Diffuse large B‐cell lymphoma/high‐grade B‐cell lymphoma (DLBCL/HGBCL) with MYC and BCL2 rearrangements (double‐hit lymphoma
Masashi Miyaoka, Joaquim Carreras, Yara Yukie Kikuti, Haruka Ikoma, Shunsuke Nagase, Atsushi Ito, Makoto Orita, Hiroshi Kawada, Rika Sakai, Yasuharu Sato, Midori Filiz Nishimura, Kunihiro Tsukasaki, Shuji Momose, Yoshihiro Kameoka, Masahiro Yoshida, Akira Satou, Seiichi Kato, Naoki Oishi, Akio Saito, Ken Sadahira, Yohei Masugi, Naoya Nakamura   +21 more
wiley   +1 more source

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Insulin Signalling‐Inducible IFITM1 Promotes Multiple Myeloma Progression and Bortezomib Resistance

Journal of Cellular and Molecular Medicine, Volume 30, Issue 11, June 2026.
ABSTRACT Insulin substantially promotes the growth of malignant cells that overexpress the insulin receptor (INSR), and insulin excess has been recognised as a cancer‐promoting factor in patients. Interferon‐induced transmembrane protein 1 (IFITM1) is also overexpressed in various cancers.
Ji‐Young Lim, Yeojin Kim, Sung‐Soo Park, Jungyeon Lee, Chang‐Ki Min   +4 more
wiley   +1 more source